$XIDE Exide Technologies (NASDAQ:XIDE) down by 7.53%,

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz

$XIDE

Exide Technologies (NASDAQ:XIDE) down by 7.53%, MannKind Corporation (NASDAQ:MNKD)

Posted by George Brook May 10, 2013 0 Comment 605 views

Hartford, CT 05/10/2013 (GDPInsider) – Exide Technologies (NASDAQ:XIDE) is down by about 7.35% after hitting a high of $1.00 during the day, and is now hovering at $0.894. The traded volumes during the day were lower than the average volume of 3.48 million, and the current trading volume is more than 2.23 million. The beta of the stock is 2.39. With a book value per share of about 3.35 the price to book value ratio of the Exide is close to 0.25 which is weak. The investors can get a clue about the stock’s performance from the investors holding in the company’s share which is close to 2.28% as of May 10, at the same time the institutional investors are holding about 78.27% in the company’s stock. The net profit margin over the trailing twelve months of the company is close to -4.69%. The analysts’ are expecting a price of $2.00 for the stock, thus we can expect the stock to rise further expect.

Exide gave a chance to the local residents to speak to its officials and its partners at the last meeting relating to the demolition of the company’s Frisco lead-acid battery recycling plant.

Is XIDE a solid investment at these levels? Get valuable updates and exclusive insights here.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Frontera Energy Set to Release Quarterly Financial Results Soon

Updated Category News Views 253

Frontera Energy Announces First Quarter Financial Results Frontera Energy Corporation (TSX: FEC) has exciting news for its shareholders and interested investors. The Company is set to unveil its financial and operational results for the first quarter, wrapping up on March 31, 2025. This significant announcement will occur after the market closes on a forthcoming Thursday...

Continue Reading
The Rising Value of Contrast Media Injectors in Healthcare

Updated Category News Views 133

Exploring the Global Market for Contrast Media Injectors The global market for contrast media injectors is on the verge of substantial growth, with projections indicating it will reach $2.1 billion in the coming years. This anticipated growth, at a compound annual growth rate (CAGR) of 7.8% from 2025 through 2033, is primarily driven by ongoing advances in technology and...

Continue Reading
Beth Wozniak Sells nVent Electric Shares Worth $884K

Updated Category News Views 158

Beth Wozniak's Recent Stock Sale at nVent Electric Beth Wozniak, Chair & CEO of nVent Electric (NYSE:NVT), executed a significant insider sale recently, as revealed in a new SEC filing. This transaction involved the offloading of 7,597 shares, with a total value of approximately $884,822. Such movements in stock ownership often pique the interest of investors, prompting...

Continue Reading
Electoral Impact of Rising Home Prices on Kamala Harris' Campaign

Updated Category News Views 211

The Impact of Home Prices on the Upcoming Election As we approach the presidential election, the role that home prices play in shaping voter sentiments is becoming increasingly evident. Recent research has shown that fluctuations in the housing market can significantly affect how voters make their choices, particularly in crucial battleground states. Current Trends in...

Continue Reading
Iambic Therapeutics Welcomes Michael Secora as CFO and CDO

Updated Category News Views 134

Iambic Therapeutics Welcomes Michael Secora as CFO and CDO Iambic Therapeutics has announced an important leadership change, appointing Michael Secora, Ph.D., as its Chief Corporate Development Officer and Chief Financial Officer. This decision comes as Iambic continues its commitment to pioneering novel medicines through its innovative AI-driven drug discovery platform....

Continue Reading